On this page
Eloralintide Quick Reference (10 mg Vial)
- Vial contents
- 10 mg Eloralintide
- Final volume
- 1 mL
- Concentration
- 10 mg/mL
- One U-100 unit
- 100 mcg in 0.01 mL
Eloralintide Dosage Chart
Dosage & Reconstitution Guide
Phase 2 Fixed-Dose Arms Using a 10 mg/mL Worked Preparation
Phase 2 Fixed-Dose Arms Using a 10 mg/mL Worked Preparation
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 48 weeks | 1 mg | 10 units (0.10 mL) |
| 48 weeks | 3 mg | 30 units (0.30 mL) |
| 48 weeks | 6 mg | 60 units (0.60 mL) |
| 48 weeks | 9 mg | 90 units (0.90 mL) |
Frequency: Once weekly in the cited phase 2 trial.[1][4]
Research reference only: The dose amounts and 48-week period come from a human phase 2 trial. Rows represent separate fixed-dose arms, not a progression. The U-100 conversions depend on the stated 1.0 mL worked preparation, which was not established by the trial publication.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 1.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Storage note: No compound-specific post-reconstitution stability or discard period has been established for this worked research-vial preparation. Follow the lot-specific product documentation for any shorter limit.
Supplies Needed
Each row is a separate 48-week fixed-dose calculation. Do not add the rows together.
- Peptide Vials (Eloralintide, 10 mg each):
- 48 weeks at 1 mg/week: 5 vials
- 48 weeks at 3 mg/week: 15 vials
- 48 weeks at 6 mg/week: 29 vials
- 48 weeks at 9 mg/week: 44 vials
- Insulin Syringes (U-100):
- 48 weekly administrations: 48 syringes
- Bacteriostatic Water (10 mL bottles):
- 5-vial calculation: 5 mL
- 15-vial calculation: 15 mL
- 29-vial calculation: 29 mL
- 44-vial calculation: 44 mL
- Alcohol Swabs:
- 48 weekly administrations at 2 swabs each: 96 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
Eloralintide Vial and Research Context
- Reconstitute: Add 1.0 mL bacteriostatic water for a worked concentration of 10 mg/mL.
- Vial contents: 10 mg Eloralintide.
- U-100 conversion: 1 unit = 0.01 mL = 100 mcg.
- Storage: Refrigerate at 2–8 °C and protect from light.
Eloralintide is an investigational amylin-receptor agonist. The trial doses are published human-study amounts; the 1.0 mL vial preparation is a worked calculation and is not a claim of formulation equivalence.[1][2][3]
Eloralintide Dose-Finding Research
Eloralintide is an investigational, selective amylin-receptor agonist. A phase 2 trial evaluated once-weekly fixed doses of 1, 3, 6, and 9 mg, along with escalation arms, for 48 weeks.[1][4] An earlier proof-of-concept study evaluated once-weekly subcutaneous administration over 12 weeks, while a discovery report described single 4 mg and 12 mg doses.[2][3]
These studies support the charted amounts and weekly frequency. They do not disclose or validate the 1.0 mL research-vial preparation used for U-100 calculations on this page.
10 mg Vial Calculation Notes
- 10 mg divided by 1.0 mL equals 10 mg/mL.
- One U-100 unit equals 0.01 mL or 100 mcg.
- 1, 3, 6, and 9 mg equal 10, 30, 60, and 90 units, respectively.
- Each 48-week vial count is rounded up to the next whole 10 mg vial.
Amylin Receptor Research Context
Investigational Status and Evidence Limits
Eloralintide remains investigational. Phase 1 and phase 2 results must be interpreted with their enrolled populations, dose-escalation rules, adverse-event monitoring, and study formulations.[1][2][4][5] A research vial requires its own identity, purity, sterility, stability, and clinical-pharmacology evidence.[11]
References
- 1Wharton et al., 2025, PMID 41207310 – Phase 2 randomized trial of once-weekly fixed and dose-escalation eloralintide regimens over 48 weeks in adults with obesity or overweight.
- 2Frias et al., 2026, PMID 41559929 – Phase 1 proof-of-concept study of once-weekly subcutaneous eloralintide over 12 weeks.
- 3Mather et al., 2025, PMID 41109426 – Discovery and clinical proof-of-concept report including single 4 mg and 12 mg eloralintide doses.
- 4ClinicalTrials.gov NCT06230523 – Registry record for the phase 2 eloralintide obesity study.
- 5ClinicalTrials.gov NCT05295940 – Registry record for an early eloralintide clinical study.
- 6Hay et al., 2015, PMID 25917562 – Review of amylin pharmacology and receptor biology.
- 7Lutz, 2012, PMID 23166332 – Review of amylin physiology and energy-balance mechanisms.
- 8Boyle et al., 2022, PMID 35066542 – Review of amylin analogs and emerging obesity pharmacotherapy.
- 9Jorsal et al., 2016, PMID 26812892 – Review of amylin and calcitonin-family receptors in metabolic disease.
- 10Mietlicki-Baase and Hayes, 2014, PMID 24262967 – Review of central amylin signaling and energy balance.
- 11U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance on evidence expected during peptide drug development.